📰 Breaking News: Lessons Learnt & Insights from DSTBTD Restructuring Plan

Appointment of liquidators (MVL)

VIMELA THERAPEUTICS LIMITED

active Company no. 13611487 Published 10 July 2026

The notice announces the appointment of James Hopkirk of Kreston Reeves LLP as liquidator for VIMELA THERAPEUTICS LIMITED in a members voluntary liquidation.

Notice details

Company
VIMELA THERAPEUTICS LIMITED
Company number
13611487
Nature of business
Research and experimental development on biotechnology
Type of liquidation
Members Voluntary Liquidation
Registered office
The Cambridge Partnership The Dorothy Hodgkin Building, Babraham Research Campus, Cambridge, CB22 3FH
Principal trading address
The Cambridge Partnership The Dorothy Hodgkin Building, Babraham Research Campus, Cambridge, Cambridgeshire, CB22 3FH
Liquidator
James Hopkirk (IP No. 21150) of Kreston Reeves LLP, 2nd Floor Maritime Place, Quayside, Chatham Maritime, Kent, ME4 4QZ
Contact
Mansi Thawani, 01634 899800, [email protected]
Appointed by
Members
Date of appointment
30 June 2026

Planning a solvent wind-down or restructure?

A members' voluntary liquidation is a solvent, orderly closure — often part of retirement, a group restructure, or moving on to the next venture. K2 has advised UK company directors since 1990 on restructuring and what comes next. If that's on your horizon, talk to us.

Related guidance

Free, practical guides from K2 on what this kind of notice means for directors.

More liquidation notices

← Back to all notices

Source: The London Gazette and Companies House. Contains public sector information licensed under the Open Government Licence v3.0. © Crown copyright. This page is provided by K2 Partners for information only and is not legal or financial advice.